Receptagen Ltd. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Receptagen Ltd.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TERENCE DALY who wrote (150)	8/2/1998 3:44:00 PM
From: Russell J. Gilbert	Read Replies (1) of 203

Terence, I too have been following PHX over the last 2 months. I have also been researching other CRO's (Clinical Research Organizations) similiar to GRN.A few of them are trading in the $4-5/US ange but a number of them are trading in the $20-40 range. And that is in US dollars. I have to assume GRN has a significant business plan after the merger is completed. It would be very helpful however to gain some insight on some of their plans. A center for CO-Q10 research is the University of Texas. Karl Folkkers is the father of CO-Q10. GRN will also get the rights to the US patent to CO-Q10 for AIDS therpy as part of the deal. Receptagen also has a patent for a water soluble form of CO-Q10 which is extremely effective in stroke victims in rebuilding brain cells and lessening damage caused by stroke. RCG has a tremendous asset portfolio. I remember when Receptagen was trading over #3.00/share when the company just started and had nothing. Now it has a wealth of assets and the price is where it is at. Go Figure!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next